Recent Press

Recent Press

February 25, 2019:
Cellanyx Appoints Guy Fish, MD, MBA to its Leadership Team.

February 21, 2019:
Cellanyx Publication Chosen As Cover of the February Edition of the Journal Urology.
Link to Article

December 13, 2018:
Cellanyx CEO Interviewed for 360Dx Article Covering Cellanyx’s Latest Publication.

December 1, 2018:
Proof-of-Concept Study of Live Tumor Cell Biomarker Test in Prostate Cancer.

November 30, 2018:
Oncozine Highlights Cellanyx’s Proof-of-Concept Results.

November 22, 2018:
Cellanyx Reports Results of Biomarker Test For Prostate Cancer.

November 21, 2018:
Cellanyx Publishes Clinical Proof-of-Concept Study in Urology of First-in-Class Live Tumor Cell, Phenotypic Biomarker Test to Risk Stratify Prostate Cancer Patients.

November 15, 2018:
BioWorld Covers Cellanyx’s Recent Publication and Key Progress.

October 31, 2018:
Urology Times Reports on Cellanyx’s Nature Biomedical Engineering Paper and Key Results.

October 10, 2018:
Science Translational Medicine Editors Cover Cellanyx’s Risk Stratification Technology.

September 18, 2018:
360Dx Highlights Cellanyx’s Live Tumor Cell Phenomics Platform.

September 17, 2018:
Biospace Covers Cellanyx’s Phenomics Analysis Platform.

September 17, 2018:
Cellanyx’s Live-Cell-Analytics Platform Covered by Digital Journal.

September 17, 2018:
Business Journals Underscores Cellanyx’s Recent Technological Progress.

September 17, 2018:
Cellanyx Publishes Details of Novel, First-in-Class Live Tumor Cell Phenotypic Test to Risk-Stratify Aggressive Vs. Indolent Disease Risk in Solid Tumors.

August 5, 2018:
Dr. David Albala presents Cellanyx’s Phenotypic & Machine Learning Platform Data to Key Opinion Leaders in Prostate Cancer at the Third Global Summit on Precision Diagnosis for Prostate Cancer.

September 12, 2017:
Cellanyx wins 1st place poster award at 2nd International Prostate Cancer Symposium and Inaugural World Congress of Urologic Oncology.

August 2, 2017:
Professor Eric Klein, MD of Cleveland Clinic’s Lerner College of Medicine Named to Cellanyx Scientific Advisory Board; SAB Chair Grannum Sant, MD, FRCS, FACS Appointed to Board of Directors.

July 21, 2017:
Cellanyx SAB Members publish article in Nature Precision Oncology describing novel approach that can revolutionize precision diagnostics and personalized therapy development.

July 21, 2017:
Cellanyx CEO addresses the importance of laboratory incubator space in Massachusetts on a Massachusetts Life Science Center Panel during BIO, 2017.

July 21, 2017:
Cellanyx takes first place at the Medstartr pitch contest during San Diego Startup Week, 2017.

July 20, 2017:
Cellanyx one of two Massachusetts companies to present at Startup Stadium at the annual BIO, 2017.

July 19, 2017:
Cellanyx one of 45 companies to present at 2017 International Cancer Cluster Showcase at BIO, 2017.

July 1, 2017:
Cellanyx places third in annual MALSI day poster competition.

June 1, 2017:
Cellanyx featured in Biospace highlighting breakthrough in culturing primary prostate biopsy cells.

June 1, 2017:
In the Journal Urology, Cellanyx reports novel method to culture Primary Prostate Biopsy Cells.

May 12, 2017:
Cellanyx scheduled to present this June at BIO International Convention 2017 Start-Up Stadium.

March 31, 2017:
Cellanyx CEO Participates in the 2017 Annual MassBio Conference Panel on Next Generation Diagnostics.

September 28, 2016:
Cellanyx Diagnostics’ Live Tumor Cell Phenotypic Risk Stratification Test Data from ‘Normal’ Tissue Samples Recognized at AdMeTech Foundation’s First Global Summit on Precision Diagnosis for Prostate Cancer with Second Place in Poster Competition.

June 1, 2016:
Cellanyx Recognized as Best Prostate Cancer Biomarker Poster Presentation at 2016 American Urological Association Annual Meeting.

July 23, 2015:
Recent Press Highlights Cellanyx’s Progress
Boston Business Journal
Wall Street Journal: Daily Startup Blog
Urology Times
Dow Jones Private Equity & Venture Capital News Portal

February 20, 2015:
Cellanyx Announces First Clinical Data with a Novel Live Tumor Cell, Phenotypic Biomarker Test in Prostate Cancer
Link to Poster

January 26, 2015:
Cellanyx gaining traction through startup competition success

July 24, 2014:
Cellanyx CEO on establishing operations in Boston

November 12, 2013:
Cellanyx announces Series A1 Funding Round

July 12, 2013:
Cellanyx joins StartX Mentor Labs

July 1, 2013:
Cellanyx welcomes Dr. David Albala and Dr. Catherine Fink to its Senior Advisory Board.

June 4, 2013:
Cellanyx named semifinalist at Founder.org competition

June 1, 2013:
Cellanyx welcomes Dr. Kevin Knopf to its Senior Advisory Board.

May 17, 2013:
Cellanyx CEO Ashok Chander interviewed for Boston Business Journal

May 1, 2013:
Cellanyx named semifinalist at Berkeley Venture Lab competition

May 1, 2013:
Cellanyx welcomes Ms. Ann Whittaker to its Senior Advisory Board.

April 26, 2013:
Cellanyx welcomes Mr. Imran Nasrullah to its Senior Advisory Board.

April 10, 2013:
Cellanyx wins M2D2 Venture Competition

April 9, 2013:
Cellanyx presents at Merck’s Early-Stage Life Sciences Technology Conference

April 4, 2013:
Cellanyx wins Boston University’s New Venture Competition

March 15, 2013:
Cellanyx welcomes Dr. Samuel Sia to its Senior Advisory Board.

March 1, 2013:
Cellanyx welcomes Dr. Una Ryan and Dr. Edward R. Berger to its Senior Advisory Board.

February 15, 2013:
Cellanyx welcomes Mr. Peter Parker to its Senior Advisory Board.

February 1, 2013:
Cellanyx welcomes Dr. Colin Brenan, Dr. Pamela Avallone, and Dr. Pravin Chaturvedi to its Senior Advisory Board.

January 17, 2013:
MedCity features Cellanyx

January 8, 2013:
Cellanyx welcomes Mr. Amar Kendale and Dr. Satish Tadikonda to its Senior Advisory Board.


Stay Informed